Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Concerning CAPOX + Nivolumab & Gastroesophageal junction adenocarcinoma (GEJ), CAPOX + Nivolumab is approved by both FDA and EMA for first‑line treatment of advanced or metastatic gastric and Gastroesophageal junction adenocarcinoma (GEJ), and CAPOX (capecitabine‑oxaliplatin) is one of the accepted chemotherapy backbones under this label, even though “CAPOX” is not named explicitly (1)
In a clinical phase III trial identified as NCT02872116, it was shown that Nivolumab is the first [Anti-PD-1 ant…